WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly ...

First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc ...

Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study. The ...

After its hearing loss treatment proved itself safe in a small phase 1 study, Frequency Therapeutics is calling in reinforcements to help it cross the finish line. The company is licensing the program ...

Author(s)Chu HT, Liang CS, Lee JT, et al. Associations between depression/anxiety, headache frequency in migraineurs: a cross-sectional study. Headache. 2018, 58(3 ...

National Correspondent; Anchor, "CBS Weekend News" Jericka Duncan is a national correspondent and anchor of the "CBS Weekend News." She's based in New York City. Chris Sopuch has taught at Oakcrest ...

Frequency of heatwaves and cumulative intensity has risen through the decades, research finds Heatwaves have increased in both length and frequency in nearly every part of the world since the 1950s, ...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...